39 results about "Kidney ischemia" patented technology

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

An early-onset method and kit for detecting renal tubular cell injury, using NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and thus readily detected in urine following tubular cell injury. NGAL protein expression was mainly detected in the proximal tubule cells, which resembled a secreted protein with a punctate distribution in the cytoplasm. Apparent NGAL in urine correlates with the amount and duration of renal ischemia and nephrotoxicemia and is a diagnostic feature of tubular cell injury and renal failure. NGAL detection is also a useful marker for monitoring nephrotoxic side effects of drugs or other therapeutic agents.

A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.

The present invention relates to application of N(6)-(2-hydroxyethyl)-adenosine (HEA) and its derivatives as an adenosine A1 receptor agonist in preparation of drug or food, the HEA and its derivatives are used in treatment of diseases relating to adenosine receptor regulator, such as insomnia, pain, convulsion, apoplexia, Parkinson's disease, opioid drug addiction and kidney ischemia reperfusion injury etc. The present invention provides a new method for treatment of the diseases relating to nervous system and kidney.

The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.

The invention discloses application of NW (Norswertianolin) in preparing a drug for preventing or treating diseases related to a CSE (Cystathionine gamma-Lyase) / H2S system. An inventor discovers thatNW is capable of combining CSE, promoting CSE enzyme activity and increasing generation of heart, blood vessel and kidney endogenous H2S, and is a new CSE enzyme activator. The NW is capable of activating a blood vessel CSE / H2S system, remarkably reducing high blood pressure, reducing vascular remodeling, inhibiting vascular inflammation, reducing atherosclerotic plaque, activating a kidney CSE / H2S system and reducing kidney ischemia reperfusion injury, so that the NW can be used for treating the diseases related to CSE / H2S.

The invention discloses application of a benzenesulfonamide compound in preparation of a medicine for treating and / or preventing acute kidney injury. The structural formula of the benzenesulfonamide compound is shown in the specification. The acute kidney injury is cisplatin or kidney ischemia reperfusion induced acute kidney injury. Experiments show that through administration of the benzenesulfonamide compound, the levels of BUN and SCr in serum of a mouse with acute kidney injury can be remarkably reduced, and the renal tissue form injury of the mouse with acute kidney injury can be remarkably relieved. The benzenesulfonamide compound has very important value for clinical prevention and treatment of acute kidney injury.

The invention provides application of trehalose in preparation of a medicine for relieving renal ischemia-reperfusion injury, and belongs to the field of biological medicines. The application proves that trehalose can alleviate ischemia-reperfusion induced acute kidney injury related diseases, including acute kidney injury renal function, oxidative stress, renal tubular cell apoptosis, renal inflammatory cell infiltration and the like, by enhancing autophagy, thereby providing a theoretical basis for widening the possible application range of trehalose. As trehalose has been approved to be a safe food component by American Food and Drug Administration at present and has been applied to food preservation and other work, it is found that effective clinical drugs are extremely likely to be provided for prevention and treatment of AKI.

The invention belongs to the technical field of kidney injury treatment drugs, and particularly relates to application of ponatinib as a drug for acute kidney injury. As an acute clinical complication, the acute kidney injury has the characteristics of being high in morbidity and high in mortality, and effective treatment drugs are not achieved at present. Related researchers in the field show that PDCD4 expression becomes higher in an acute kidney injury model, and it is indicated that the PDCD4 plays an important role in the physiological mechanism related to the acute kidney injury. The situation that the PDCD4 aggravates the kidney injury by regulating an Fgr-Stat3-Notch1 pathway is further confirmed. The confirmation of the regulatory mechanism provides a basis for the treatment of the acute kidney injury. According to the research results, the ponatinib, an Fgr kinase inhibitor, is adopted to treat the acute kidney injury, the drug has a significant protective effect on the injury caused by kidney ischemia reperfusion, and it is indicated that the drug intervention in Fgr can prevent and treat the acute kidney injury.

The invention discloses application of hexarelin to preparing kidney ischemia reperfusion injury protecting drugs / drug combinations and belongs to the field of biological medicines. According to the application, the hexarelin is proved to possibly have protecting effects on rate ischemia reperfusion induced acute kidney injury; data prove that expression of SFN (stratifin) gene in a kidney ischemia reperfusion model is significantly increased, and with intervention of the hexarelin, is more significantly increased, while expression of apoptosis promoting genes of Bax, Bad and caspase3 are down-regulated, so that the hexarelin can protect kidney ischemia reperfusion injury by inhibiting apoptosis, and further by means of the molecular docking technology, possibility of interaction between hexarelin molecules and a 14-3-3 sigma protecting structure coded by the SFN gene can be testified, and a theoretical foundation for enlarging the possible application range of the hexarelin can be provided. The application of the hexarelin to preparing the kidney ischemia reperfusion injury protecting drugs / drug combinations can be applied to theoretical research and clinical application of kidneyischemia reperfusion injury and provide the theoretical foundation for enlarging the possible application range of the hexarelin.

The present invention provides a prophylactic or therapeutic agent for a kidney disease, comprising AIM or a partial peptide thereof, or a nucleic acid comprising a base sequence encoding the same, or a screening method for a prophylactic or therapeutic agent for a kidney disease, comprising using an animal obtained by subjecting a non-human mammal deficient in AIM expression to unilateral ureteral obstruction or transient kidney ischemia / reperfusion and the like.

The invention discloses application of linarin to preparing kidney tubular epithedial cell ischemia reperfusion injury protecting drugs / drug combinations and belongs to the field of biological medicines. The application proves the possibility of protecting effects of the linarin on kidney ischemia reperfusion, and through data, discovers that reducing expression of ETS2 proteins can inhibit proinflammatory factors IL-12 and accordingly inhibit inflammation to achieve the protecting effects on kidney tubular epithedial cell ischemia reperfusion injury; further only through the molecule dockingtechnology, possibility of interaction between the linarin and the ETS2 proteins is analyzed, and a theoretical foundation for enlarging the possible application range of the linarin is provided. Theapplication of the linarin to preparing the kidney tubular epithedial cell ischemia reperfusion injury protecting drugs / drug combinations can be applied to theoretical research and clinical treatmentof kidney ischemia reperfusion injury and provide the theoretical foundation for enlarging the possible application range of the linarin.

Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, the signals that initiate these events remain poorly understood. The inventors identify the nuclear alarmin interleukin (IL)-33 as an initiation factor of tissue injury and also as a major amplification factor of the innate immune response triggered by experimental kidney ischemia-reperfusion in mice. In mice lacking IL-33, IRI is reduced, as attested by early decreased tubular cell injury, and by subsequent decreased infiltration of IFN-γ / IL-17A-producing neutrophils and preservation of renal functions. These findings led the inventors to propose that endogenous IFN-33 contributes to kidney IRI by promoting iNKT cell recruitment and cytokine production, resulting in neutrophil infiltration and activation at the injury site. Accordingly, the present invention relates to antagonists of IL-33 for use in methods for preventing ischemia reperfusion injury in an organ.

The invention provides an application of a recombinant human myeloid-derived growth factor in preparation of a medicine for treating renal ischemia reperfusion injury. The recombinant human medullary-derived growth factor can reduce serum creatinine and urea nitrogen levels of mice suffering from renal ischemia reperfusion injury, improves renal functions after renal ischemia reperfusion injury, has a kidney protection effect and can relieve oxidative stress injury caused by renal ischemia reperfusion injury. The traditional Chinese medicine composition brings hopes for improving the life quality of kidney transplantation patients and prolonging the survival time of transplanted kidneys, and also has a certain far-reaching influence on prevention and treatment of ischemia reperfusion injuries of other tissues and organs.

The present invention is in the technical field of transplantation, and more particularly relates to the prognosis of a renal transplantation, and to the prevention of renal ischemia and reperfusion injury (IRI) prior to renal transplantation. The invention is more particularly based on the findings that the circulating level of ferritin in a patient is predictive of the outcome of renal transplantation, and that an iron administration to said patient prior to transplantation can prevent IRI.

The present invention provides a method of preventing, reducing or attenuating acute kidney injury in a subject at risk of experiencing a transient increase in kidney ischemia or hypoxia, comprising administering to the subject an effective amount of an agent that binds to and neutralizes endogenous ouabain (EO).

Described are MMP8 inactivating antigen binding proteins, such as antigen binding proteins comprising an amino acid sequence that comprises 4 framework regions and 3 complementary determining regions; further described is the use of such antigen binding proteins to treat inflammation, such as, but not limited to, systemic inflammatory response syndrome, sepsis, LPS induced inflammation, renal ischemia / reperfusion injury, ventilation induced lung injury, periodontal inflammation, rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, Lyme arthritis and osteoarthritis.

The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.

The invention discloses application of scutellarin to preparing kidney ischemic reperfusion injury preventing / protecting drugs / drug combinations and belongs to the field of biological medicines. The application proves possibility of the preventing / protecting effects of the scutellarin on human ischemic reperfusion-induced acute kidney injury; data show that the content of Nrf2 (nuclear factor erythroid-2-related factor 2) proteins in a kidney ischemic reperfusion model is significantly reduced, and after the scutellarin is applied, expression of Nrf2 genes can have change of statistical significance, and by means of the molecule docking technology, possibility of interaction of scutellarin molecules and the protein structure is testified, and a theoretical foundation for enlarging the possible application range of the scutellarin can be provided. The application of the scutellarin to preparing kidney ischemia reperfusion injury preventing / protecting drugs / drug combinations can be applied to theoretical research and clinical treatment of kidney ischemic reperfusion injury and provide the theoretical foundation for enlarging the possible application range.

The invention discloses an application of GW3965 for preparation of medicines preventing and treating kidney ischemia reperfusion injuries. The GW3965 is a selective LXR agonist, and acts on LXR[alpha] and LXR[beta]. Significant medicine effects of the GW3965 allow the GW3965 to have a potential for development into as a medicine preventing and treating kidney injuries, and allow the GW3965 to be a research direction of new medicines preventing and treating kidney injuries.

The invention relates to the technical field of biomedicine, in particular to tetranectin-mimicking peptide TNP and its application in treating diseases caused by the release of HMGB1 from vascular endothelial cells. The sequence of the acetylated tetranectin mimetic peptide at the nitrogen end is Ac‑QPDGGKTENCAVLSGAANGKWFDKRCRDK‑biotin. The acetylated tetranectin mimetic peptide TNP can effectively prevent the hydrolysis of TNP and prolong its half-life to improve the biological efficacy of the drug. TNP is in use When preparing drugs for the treatment of sepsis and other diseases, it can effectively inhibit the release of HMGB1 from vascular endothelial cells, reduce the concentration of extracellular HMGB1, and reduce the death rate of septic mice, and can almost completely block renal ischemia-reperfusion in mice. Changes in plasma urea nitrogen and creatinine can reduce renal tubular necrosis after ischemia, achieve the purpose of treating acute kidney injury, and provide a new way for the diagnosis and treatment of human diseases caused by the release of HMGB1 from vascular endothelial cells.

An application of Ponatinib as a drug for acute kidney injury. Since PDCD4 aggravates the kidney injury by regulating an Fgr-Stat3-Notch1 pathway, the ponatinib, an Fgr kinase inhibitor, is adopted to treat the acute kidney injury. The drug has a significant protective effect on the injury caused by kidney ischemia reperfusion, and it is indicated that the drug intervention in Fgr can prevent and treat the acute kidney injury.

The invention discloses application of gambogic acid in preparation of a medicine for preventing or treating kidney ischemia-reperfusion injury. According to the application, animal experiments and cell experiments are carried out on gambogic acid which is an extract of traditional Chinese medicine gamboge, it is found that a certain dosage of gambogic acid can remarkably relieve mouse kidney ischemia-reperfusion injury, the protection effect is mainly achieved by enhancing mitochondrial autophagy, and important technical support is provided for preventing or treating kidney IRI. Clinically, an injection can be prepared from the gambogic acid freeze-dried powder injection, the injection is administrated through intravenous injection, the administration time is at least one time of intravenous injection on a donor within 24 hours before a transplanted organ is obtained, and the effective dose of the intravenous injection is 4-40 mg / m < 2 > each time. The new application of the gambogic acid in kidney protection and repair is proved, and a new selection scheme or thought is provided for medical researchers to clinically explore and treat ischemia-reperfusion injury of heart, liver, lung and other organs.

The invention relates to the field of medicine, in particular to medicine application of a beta subunit of truncated type sodium-potassium atpase. The medicine application of the beta subunit of the truncated type sodium-potassium atpase on the protection effect of ischemia reperfusion injury of islet transplantation is achieved. Protection of tNKA beta on islet cell ischemia reperfusion injury is cleared, and the measure for preventing kidney ischemia reperfusion injury is further optimized. The mechanism of the tNKA beta on the protection effect on the islet cell ischemia reperfusion injury is disclosed, and a theoretical basis is provided for clinical experiments and research. The medicine application of a beta subunit of the truncated type sodium-potassium atpase has the advantages that the situation of inanition can be effectively relieved in the pancreatic islet ischemia reperfusion effect, and the anoxic situation is relieved.

The invention discloses a compound used as a dual inhibitor for RAAS (rennin angiotensin aldosterone system) and particularly relates to a compound shown in formula (I), a stereisomer thereof or a pharmaceutically acceptable salt thereof. The compound can be used for treating and blocking RAS-associated diseases such as hypertension and heart disease, can be used for preventing or treating hypertension, congestive heart failure, pulmonary hypertension, renal insufficiency, renal ischemia, kidney failure, renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis, myocardial ischemia, cardiomyopathy, glomerulonephritis, renal colic, complications such as nephropathy caused by diabetes, vasculopathy, vasculopathy, glaucoma, intraocular pressure elevation, atherosis, restenosis after revascularization, complications after blood vessel or cardiac operation, erectile dysfunction, hyperaldosteronism, lung fibrosis, scleroderma, anxiety, cognitive disorder, complications caused by immunosuppressor treatment as well as other known diseases associated with the rennin angiotensin aldosterone system.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of medicine for treating acute kidney injuries. The effective ingredients of the traditional Chinese medicine composition are prepared from, by weight, 1-2 parts of borneol, 1-2 parts of musk, 3-5 parts of cooptis chinensis, 3-5 parts of scutellaria baicalensis, 3-5 parts of fructus gardenia, 3-5 parts of radix curcumae, 1-3 parts of pearls, 7-9 parts of concentrated cornu bubali powder and 3-5 parts of calculus bovis. The pharmacodynamics study shows that the traditional Chinese medicine composition has a remarkable protection function on mouse acute kidney injuries caused by kidney ischemia reperfusion, vancomycin and cis-platinum, increase of blood urea nitrogen, serum creatinine, TNF-alpha and IL-1beta caused by the kidney injuries can be remarkably reduced, the content of serum malonaldehyde and NO in kidney tissue is reduced, and the sudismase level in the kidney tissue is improved.